Free Trial

Day One Biopharmaceuticals Q3 2024 Earnings Report

Day One Biopharmaceuticals logo
$12.53 -0.11 (-0.87%)
(As of 03:58 PM ET)

Day One Biopharmaceuticals EPS Results

Actual EPS
$0.38
Consensus EPS
-$0.20
Beat/Miss
Beat by +$0.58
One Year Ago EPS
-$0.54

Day One Biopharmaceuticals Revenue Results

Actual Revenue
$93.76 million
Expected Revenue
$15.05 million
Beat/Miss
Beat by +$78.71 million
YoY Revenue Growth
N/A

Day One Biopharmaceuticals Announcement Details

Quarter
Q3 2024
Time
After Market Closes
AI Crypto Tool Could Send One Coin SOARING… (Ad)

The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto project

Discover our #1 crypto pick before it's too late.

Day One Biopharmaceuticals Earnings Headlines

Day One price target lowered to $34 from $39 at JonesResearch
"X-Ray Vision" could find thousands of hidden market opportunities
Let me show you how I trade with “X-Ray vision.” You see, most “trend” traders only use one trend filter when looking for an optimal buy signal. And that can be a big mistake because you can’t see if you’re in a “True Trend.” But my newest trading tool is designed to only target the best, most stable stocks… Using 3 trend filters… which are these green, yellow, and red lines.
Day One Biopharmaceuticals (DAWN) Gets a Buy from Piper Sandler
See More Day One Biopharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Day One Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Day One Biopharmaceuticals and other key companies, straight to your email.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

View Day One Biopharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings